Bank of America has revised its price target for Regeneron Pharmaceuticals (REGN, Financial) downward to $547 from the previous $575. The change is driven by a projected decrease in earnings visibility and a squeeze in the pharmaceutical sector's average price-to-earnings (P/E) ratio, influenced by tariff issues and drug pricing pressures.
Furthermore, the ongoing analysis ahead of Regeneron's upcoming first-quarter earnings report has led to revised estimates for its U.S. Eylea sales. This adjustment comes in response to the anticipated impact of the cessation of patient assistance funds. Despite these developments, Bank of America maintains its Underperform rating on the stock, reflecting continuing caution around its financial outlook for 2025.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 25 analysts, the average target price for Regeneron Pharmaceuticals Inc (REGN, Financial) is $909.08 with a high estimate of $1,152.00 and a low estimate of $575.00. The average target implies an upside of 65.50% from the current price of $549.28. More detailed estimate data can be found on the Regeneron Pharmaceuticals Inc (REGN) Forecast page.
Based on the consensus recommendation from 28 brokerage firms, Regeneron Pharmaceuticals Inc's (REGN, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Regeneron Pharmaceuticals Inc (REGN, Financial) in one year is $906.31, suggesting a upside of 65% from the current price of $549.28. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Regeneron Pharmaceuticals Inc (REGN) Summary page.
